Icon buys second firm this week

The Irish clinical trials group Icon has made its second acquisition in the space of a week, and is paying $5.8 million (€5.9 million) for YRCR, a British pharmaceutical regulatory affairs consulting group. Based in Henley in the UK, YRCR provides advice and support, including marketing authorisation applications for European, American and Japanese clients.